Show simple item record

dc.contributor.authorVogel, A.
dc.contributor.authorChen, L. T.
dc.contributor.authorHe, A. R.
dc.contributor.authorKim, J. W.
dc.contributor.authorChen, M. H.
dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorShimizu, S.
dc.contributor.authorGillmore, R.
dc.contributor.authorRey, F.
dc.contributor.authorKim, H.
dc.contributor.authorXiong, J.
dc.contributor.authorMakowsky, M.
dc.contributor.authorRokutanda, N.
dc.contributor.authorCohen, G.
dc.contributor.authorOh, D. Y.
dc.date.accessioned2022-11-30T10:21:25Z
dc.date.available2022-11-30T10:21:25Z
dc.date.issued2022en
dc.identifier.citationVogel A, Chen LT, He AR, Kim JW, Chen MH, McNamara MG, et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301241.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.4075en
dc.identifier.urihttp://hdl.handle.net/10541/625802
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4075en
dc.titleRegional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentHannover Medical School, Hannover, Germanyen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record